<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VALGANCICLOVIR HYDROCHLORIDE</span><br/>(val-gan-ci'clo-vir)<br/><span class="topboxtradename">Valcyte<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral agent</span><br/><b>Prototype: </b>Acyclovir<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>450 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Rapidly converted to ganciclovir after oral administration by intestinal and hepatic enzymes. In cells infected with cytomegalovirus
         (CMV) ganciclovir is phosphorylated to ganciclovir triphosphate that inhibits viral DNA synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antiviral drug active against cytomegalovirus (CMV). Prevents replication CMV DNA, thus inhibiting replication of the virus.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of CMV retinitis; prevention of CMV disease in high-risk kidney, kidney-pancreas, and heart transplant patients
         (not effective in liver transplants).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to valganciclovir, ganciclovir, or acyclovir. Not recommended for persons on hemodialysis; renal failure;
         dental work; antimicrobial resistance; neutropenia, thrombocytopenia; pregnancy (category C), females of childbearing age;
         lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired kidney function; older adults; dental disease; anemia; leukopenia; bone marrow depression; concomitant use of myelosuppressive
         drugs; irradiation. Safety and efficacy in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Cytomegalovirus Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 900 mg once daily with food, starting within 10 d of transplantation until 100 d posttransplantation<br/><br/><span class="indicationtitle">Cytomegalovirus Retinitis Induction</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 900 mg b.i.d. with food times 21 d<br/><br/><span class="indicationtitle">Cytomegalovirus Retinitis Maintenance</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 900 mg q.d. with food<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 4059 mL/min: 450 mg b.i.d. (induction) or q.d. (maintenance) 2539 mL/min: 450 mg q.d. (induction) or q2d (maintenance)
               1024 mL/min: 450 mg q2d (induction) or twice weekly (maintenance)<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Exercise caution in handling tablets. Do not crush or break tablets. Avoid direct contact of crushed or broken tablets with
            skin or mucous membranes.
         </li>
<li>Give with food.</li>
<li>Do not give to patients on hemodialysis.</li>
<li>Store at 25°30° C (77°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Fever,</span> local and systemic infections, hypersensitivity reactions. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache, insomnia,</span> peripheral neuropathy, paresthesia, convulsions, psychosis, confusion, hallucinations, agitation. <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea, nausea, vomiting, abdominal pain</span>. <span class="typehead">Hematologic:</span>
<span class="speceff-common">Neutropenia, anemia,</span>
<span class="speceff-life">thrombocytopenia</span>, pancytopenia, <span class="speceff-life">bone marrow suppression, aplastic anemia</span>. <span class="typehead">Special Senses:</span>
<span class="speceff-common">Retinal detachment</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">antineoplastic agents</span>, <b>amphotericin B,</b>
<b>didanosine,</b>
<b>trimethoprim-sulfa-methoxazole (TMP-SMZ),</b>
<b>dapsone,</b>
<b>pentamidine,</b>
<b>probenecid,</b>
<b>zidovudine</b> may increase bone marrow suppression and other toxic effects of valganciclovir; may increase risk of nephrotoxicity from
      <b>cyclosporine;</b>
<span class="classification">antiretroviral agents</span> may decrease valganciclovir levels; valganciclovir may increase levels and toxicity of <span class="classification">antiretroviral agents</span>; may increase risk of seizures due to <b>imipenem-cilastatin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed from GI tract, 60% reaches systemic circulation as ganciclovir. <span class="typehead">Onset:</span> 38 d. <span class="typehead">Peak:</span> 13 h. <span class="typehead">Duration:</span> Clinical relapse can occur 14 d to 3.5 mo after stopping therapy; positive blood and urine cultures recur 1260 d after
      therapy. <span class="typehead">Distribution:</span> Distributes throughout body including CSF, eye, lungs, liver, and kidneys; crosses placenta in animals; not known if distributed
      into breast milk. <span class="typehead">Metabolism:</span> Metabolized in intestinal wall to ganciclovir, ganciclovir is not metabolized. <span class="typehead">Elimination:</span> 9499% of dose is excreted unchanged in urine. <span class="typehead">Half-Life:</span> 4 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Withhold drug and notify physician for any of the following: Absolute neutrophil count 3, platelet count 3, hemoglobin 
         </li><li>Monitor for S&amp;S of bronchospasm in asthma patients; notify physician immediately.</li>
<li>Lab tests: Baseline and frequent serum creatinine or creatinine clearance, CBC with differential, platelet count, Hct &amp; Hgb.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Schedule ophthalmologic follow-up examinations at least every 46 wk while being treated with valganciclovir.</li>
<li>Keep all scheduled appointments for laboratory tests.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Report any of the following immediately: unexpected bleeding, infection.</li>
<li>Use effective methods of contraception (barrier and other types) during and for at least 90 d following treatment.</li>
<li>Discontinue drug and notify physician immediately in the event of pregnancy.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>